A360
Key Takeaways✦ Atlas AI
01
The CDC reports a significant rise in extensively drug-resistant Shigella infections in the U.S., with XDR strains increasing from 0% to 8.5% of cases between 2011 and 2023, posing a serious public health challenge.
02
This surge in XDR Shigella is concerning because there are no FDA-approved oral antibiotics for treatment, leaving limited options like intravenous carbapenems for severe cases and highlighting a critical gap in antimicrobial therapies.
03
The shift in epidemiology, with XDR cases predominantly affecting adult males and being domestically acquired, necessitates enhanced surveillance, targeted prevention strategies, and improved antimicrobial susceptibility testing to curb its spread.
Atlas AI
The US Centers for Disease Control and Prevention (CDC) is reporting a rise in extensively drug-resistant (XDR) Shigella infections in the United States, according to an analysis of laboratory isolates collected between 2011 and 2023.
XDR Shigella is defined as resistant to five commonly used antibiotics: ampicillin, azithromycin, ceftriaxone, ciprofloxacin, and trimethoprim-sulfamethoxazole. The CDC also says there are currently no FDA-approved oral antibiotics available for XDR Shigella infections.
XDR strains rose to 8.5% of isolates in 2023
The CDC analyzed 16,788 Shigella isolates collected through PulseNet from 2011 to 2023. The proportion identified as XDR rose from 0% during 2011–2015 to 8.5% in 2023.
ATLAS SIGNAL│Public Health│High│1–3 months
16d
Rising Drug-Resistant Shigella in US Highlights Global Antimicrobial Resistance Threat
The increase in extensively drug-resistant (XDR) Shigella infections in the United States, with no FDA-approved oral antibiotics for treatment, underscores the growing global challenge of antimicrobial resistance (AMR). While specific to the US in this report, the emergence of XDR pathogens in one region often foreshadows international spread and exacerbates public health crises worldwide, impacting healthcare systems and economic stability.
1 story
Who is being affected has shifted
The CDC report indicates the epidemiology has changed compared with prior US outbreaks, which were largely drug-susceptible and primarily affected children. In contrast, XDR Shigella cases have mostly occurred in adult males, with an average age of 41.
Travel history data suggest most cases are acquired domestically. Among people with available data, 76.2% reported no recent domestic travel and 82.4% reported no recent international travel.
Limited treatment options
Because antibiotic options are limited for XDR Shigella, treatment may rely on supportive care. For severe infections requiring hospitalization, intravenous carbapenems are described as a reliable option.
The CDC said stronger surveillance, routine antimicrobial susceptibility testing, and timely reporting are needed, along with targeted prevention measures to reduce further spread.
